Journal of Pediatric Gastroenterology and Nutrition · 2006 · 23 citations · 9 references
MedicineHematologyImmunologyAutoimmunityHepatologyImmunopathologyAutoantibodiesAutoimmune DiseasesAutoimmune Liver Disease TreatmentCirrhosisLiver DiseaseAutoimmune CirrhosisAutoimmune Hepatitis TreatmentDrug-induced Autoimmune HepatitisDrug-induced Serum SicknessIsolated Prolonged Prothrombin TimeMinocycline TherapyPediatric Autoimmune Hepatitis
INTRODUCTION Minocycline is an antibiotic commonly used in the treatment of acne vulgaris. It is known to have adverse side effects such as hypersensitivity reactions, gastrointestinal intolerance, serum-sickness-like reaction, single organ dysfunction, benign intracranial hypertension, pneumonitis, and autoimmune hepatitis. In general, recovery from autoimmune hepatitis has been said to be good after discontinuation of minocycline. Our case represents a young man who was treated with minocycline for acne and developed drug-induced autoimmune hepatitis and cirrhosis. CASE REPORT A previously healthy 15 year-old white male presented to his primary care physician with a several month history of increased bruising, petechiae, and occasional epistaxis. At that time, his platelet count was 75,000/mm3 with an otherwise normal complete blood count (CBC). He also had mild prolongation of prothrombin time and partial thromboplastin time, an alanine transaminase (ALT) of 67 U/L, and an aspartate transaminase (AST) of 73 U/L. His total serum bilirubin was 2.5 mg/dL with a direct of 0.3 mg/dL. He was referred to a pediatric hematologist for evaluation. There was no history of excessive bleeding with dental work or with circumcision. He had sprained his ankle twice in the past 2 to 3 months, after which he had taken ibuprofen and naproxen. He had been taking minocycline 100 mg daily for acne for the prior 12 months. Family history included members with hypertension and prostate cancer in the maternal grandfather. There was no family history of autoimmune disorders, leukemia, anemia, thrombocytopenia, or liver disease. Physical examination was normal except for hypertension (164/91 mm Hg) and bruising and petechiae on his extremities and trunk related to minor trauma. A CBC was within normal limits except for a platelet count of 82,000/mm3. His International Normalized Ratio (INR) was mildly prolonged, with a normal partial thromboplastin time and thrombin time. Factors II, VII, VIII, and IX were mildly decreased. Tests for von Willebrand disease were normal. His antinuclear antibody titer (ANA) was positive at 1:40, double stranded DNA antibody was positive at 38 IU/ml, anti-smith antibody was negative, erythrocyte sedimentation rate was normal, and C-reactive protein was elevated at 0.71 mg/dL. Liver biochemistry revealed an ALT of 83 U/L, AST of 79 U/L, and total bilirubin of 4.2 mg/dL, with a normal direct bilirubin. Alkaline phosphatase was normal at 366 U/L. Human leukocyte antigen class 1 antibody screen and platelet antibody detection were both negative. A tentative diagnosis of thrombocytopenia and coagulopathy of unknown etiology was made. Daily supplements of vitamin K were started. He was referred to a pediatric nephrologist for further evaluation of his persistent hypertension. The echocardiogram was normal. Abdominal ultrasound demonstrated splenomegaly and asymmetric kidney length with a normal right kidney, an enlarged left kidney, and a normal liver. A second review of the abdominal ultrasound revealed echogenicity, coarse echo texture, and prominence of the periportal tissue in the right lobe of the liver with a normal left lobe. Urinalysis, urine vanillylmandelic acid and homovanillic acid levels were all normal. He was persistently hypertensive at 161/106 mm Hg. He continued to have scattered ecchymoses on his limbs. A captopril renogram was performed and demonstrated right renal artery stenosis, with the left kidney providing 75% of kidney function and the right providing only 25%. Antihypertensive medication with amlodipine was started. He was hospitalized for 3 days at Fairview-University Medical Center for further radiologic evaluation and hypertension control. On admission, the physical examination was normal except for hypertension. Laboratory tests revealed a platelet count of 94,000/mm3, normal electrolytes, blood urea nitrogen, and creatinine. ALT, AST, and total bilirubin continued elevated at 62 U/L, 91 U/L, and 2.2 mg/dL, respectively. Alkaline phosphatase was normal. INR was mildly prolonged at 1.12, with partial thromboplastin time of 34 seconds and normal thromboplastin time of 14.8 seconds. Antineutrophil cytoplasmic antibody was negative, and complement levels were normal. Intravenous labetalol was added to his antihypertensive regimen, and mean arterial pressure decreased from 130 to 100 mm Hg. Renal angiogram showed a focal, concentric 80% linear stenosis in the mid-portion of the right renal artery consistent with fibromuscular dysplasia. Angioplasty was performed with good radiologic and clinical results. His antihypertensive medications were discontinued. At discharge, his unconjugated bilirubin remained elevated and was thought to be related to Gilbert syndrome. He continued on minocycline for acne. Four months later, he was referred to a pediatric rheumatologist for evaluation of possible systemic lupus erythematosus. Evaluation by pediatric rheumatology demonstrated persistently elevated transaminases, persistent thrombocytopenia, with platelets count of 92,000/mm3, positive ANA titer of 1:640, and positive antihistone antibodies. Antidouble stranded DNA, anticentromere, antiribonucleoprotein, anti-Scl-70, anti-smith antibodies, and lupus anticoagulant were all negative. These results were consistent with drug-induced lupus rather than systemic lupus erythematosus. The patient had stopped minocycline 4 months before this evaluation, and it was recommended that he avoid further minocycline therapy. He was then seen by a pediatric gastroenterologist for evaluation of continued elevation in liver enzymes, thrombocytopenia, and probable autoimmune liver disease. Further history revealed that no liver enzymes had been performed before starting minocycline. His physical examination revealed a palpable liver 2 cm below the right costal margin and an enlarged spleen 3 cm below the left costal margin. He appeared slightly icteric with mild facial acne. ALT and AST remained high at 143 and 174, respectively. Screening for hepatitis B and C were negative, alpha-1-antitrypsin level was normal, as was ceruloplasmin. His smooth antibody titer was 1:40. Immunoglobulin G level was elevated at 1,710 mg/dL. Liver biopsy demonstrated chronic autoimmune hepatitis, moderate activity grade 2 of 4 and cirrhosis stage 4 of 4 (Fig. 1). His thrombocytopenia was attributed to splenic sequestration associated with cirrhosis.FIG. 1: (A) Liver tissue from patient described, showing moderate to severe lobular activity with apoptotic bodies and cirrhosis stage 4 of 4. Portal and periportal infiltrate is seen, with interface hepatitis. (B) Hepatocyte swelling with lymphoplasmacytic infiltrate.He began immunosuppressive therapy with 6-mercaptopurine and prednisone. Eventually, his prednisone was tapered. His liver transaminases showed a good response initially to the immunosuppressive therapy, with ALT decreasing to 41 U/L and AST to 60 U/L. The indirect bilirubin remained elevated at 4.0 mg/dL. He was weaned from prednisone and continues on immunosuppressive therapy 2 years after diagnosis. His most recent ALT was 54 U/L and AST 68 U/L. Six months before this writing, his hypertension returned, and he was found to have recurrent renal artery stenosis. After dilation, he continues to take Enalapril for hypertension, which is well controlled. DISCUSSION Minocycline, a semisynthetic tetracycline, is an antibiotic commonly used to treat acne vulgaris. It is frequently prescribed not only for its effectiveness against Propionibacterium acnes and coagulase-negative Staphylococcus, but also for 11 to 13 hour half life, which allows for a once to twice a day dosing schedule. As in our patient, the drug is used in young and otherwise healthy individuals, and treatment range is typically months to years. A list of recognized side effects includes hyperpigmentation, photosensitivity, hypersensitivity reactions (rashes) (1,2), gastrointestinal intolerance, minocycline induced autoimmune hepatitis (3-8), minocycline induced lupus (9,10), serum-sickness-like reaction (9,11), single organ dysfunction (9), benign intracranial hypertension (12), and pneumonitis (9). Our patient fits most of the criteria for autoimmune hepatitis (13) with evidence of chronic active hepatitis and cirrhosis on liver biopsy, elevated AST and ALT, normal alkaline phosphatase level, elevated immunoglobulin G level, positive ANA titer and smooth muscle antibody titer, negative viral serology, and no history of drinking alcohol. The patient does, however, have a history of taking minocycline, a potentially hepatotoxic drug. Thus, our patient fits the criteria of a drug-induced autoimmune hepatitis. What makes our case significant is that he ultimately developed cirrhosis, a rare complication of minocycline-induced autoimmune hepatitis. Our case, similar to others in the literature, is linked to minocycline exposure for the treatment of acne. There have been multiple cases reported of autoimmune hepatitis associated with minocycline. In a case series by Teitelbaum et al. (3), three adolescents (ages 15-16 years) being treated for acne with minocycline 100 to 200 mg/d for 12 to 20 months developed autoimmune hepatitis that met the International Autoimmune Hepatitis Group criteria. Similar to our patient, all three had a positive ANA titer, a positive anti-smooth muscle antibody titer, and hypergammaglobulinemia. Liver biopsy was performed in two of the patients and demonstrated severe chronic lymphoplasmacytic inflammation, fibrosis and necrosis. Clinical symptoms included fever, polyarthralgia, rash, fatigue, jaundice, anorexia with weight loss, diarrhea, nausea, and abdominal pain. One patient had complete resolution of symptoms and normalization of laboratory values with discontinuation of minocycline. The other two patients required immunosuppressive therapy to attain resolution of symptoms and normal lab values. Malcolm et al. (8) reported six cases (3 males and 3 females) of minocycline-induced liver injury, with five of the cases involving patients ages 15 to 20 years old. Minocycline dose was 100 to 200 mg/d, and treatment duration ranged from 4 weeks to 2 years. Three of the patients had positive ANA titers. In all patients, viral serology was negative, alcohol consumption was minimal, and there was no history of other hepatotoxic medications. Gamma globulin or immunoglobulin G levels were not mentioned. Males and females were affected equally. Liver biopsy was performed on two of the patients and revealed chronic active hepatitis in one patient and portal and lobular hepatitis in the other. A compilation of clinical symptoms included nausea, anorexia, fatigue, abdominal pain, rash, fever, jaundice, polyarthralgia, and headache. One of these patients was rechallenged with minocycline, and the ALT increased fourfold within a 2 week period. This same patient also required immunosuppressive therapy. Another patient received 5 weeks of oral corticosteroid for a drug-related vasculitic rash. Except for the above-mentioned immunosuppressive treatments, all patients recovered after withdrawal of minocycline with normal liver tests for more than 12 months. Gough et al. (14) reported 11 cases of minocycline-induced systemic lupus erythematosus and 16 cases of autoimmune hepatitis from the United Kingdom through April 1994. Five of these cases of autoimmune hepatitis were adolescents, with ages ranging from 16 to 18 years old. There was a mild female predominance of 55%. Duration of minocycline exposure ranged from 9 days to 3 years with dosage range of 50 to 200 mg/d. One patient took a 6 g overdose. Many patients recovered after withdrawal the drug; however, as with our patient, some required prolonged immunosuppressive therapy. The features described included rash, fever, polyarthralgia, jaundice, and malaise. Two patients died while on minocycline for acne, and one patient required a liver transplant. Five patients had recurrence on rechallenge with minocycline. The evidence of positive rechallenge strongly supports a causal relationship between minocycline and autoimmune hepatitis. Furthermore, that most patients recovered after withdrawal of drug also suggests a drug reaction. Given the frequency of hepatic injury related to minocycline use, it is essential that dermatologists and pediatricians be aware of the risk of minocycline therapy. Patients who develop rash, arthralgias, malaise, or unexplained fever should stop taking minocycline immediately and receive a full evaluation. Recommendations for surveillance during isotretinoin therapy, a drug that also causes hepatitis, include routine liver tests before, during, and after completion of treatment (15). Currently, there is no way to predict which patients are at risk of developing autoimmune hepatitis with minocycline exposure. With increased prescriptions written for minocycline for acne treatment, it is imperative to determine the prevalence of minocycline-induced autoimmune hepatitis. If the prevalence is high, monitoring of liver enzymes for those treated with the drug may be warranted. Detrimental outcomes such as the cirrhosis of our patient could possibly have been averted or at least further liver damage prevented with routine liver panel screening.
9
Minocycline induced autoimmune hepatitis and systemic lupus erythematosus-like syndrome: Table 2
Andrew Gough, Stephen Chapman, K. Wagstaff et al. · BMJ · 1996 · 314 citations
Skin pigmentation due to minocycline treatment of facial dermatoses
C. M. Dwyer, A.M. CUDDIHY, Ron Kerr et al. · British Journal of Dermatology · 1993 · 91 citations